SAPHENUS MEDICAL TECHNOLOGY GMBH

Their core work

Saphenus Medical Technology develops intelligent prosthetic and bionic feedback systems for people with limb loss and diabetes-related complications. Their core work centres on restoring or simulating sensory feedback through prostheses — bridging the gap between mechanical replacement and neurological perception. They progressed from a feasibility-stage intelligent prosthesis concept (IPS, 2018) to a full-scale bionic feedback system targeting both amputees and diabetics (BFS, 2020–2022), suggesting a product development company at an advanced commercialisation stage. As an Austrian medical technology SME, they operate as both innovator and project lead, securing EU funding to bring proprietary device technology to market.

What they specialise in

How they've shifted over time

Saphenus entered H2020 in 2018 with a focused feasibility study on an intelligent prosthesis system (IPS), a typical Phase 1 proof-of-concept. By 2020, they had scaled to a EUR 1.8M Phase 2 project (BFS) that broadened the target population from amputees alone to include diabetics — a significant market expansion. This shift suggests the company identified that the core bionic feedback technology has applications beyond limb replacement, potentially in diabetic neuropathy monitoring or sensory augmentation for at-risk patients. No keyword metadata was available to confirm finer technical shifts, so this reading is based solely on project titles and funding trajectory.

Saphenus is moving from single-indication prosthetics toward a platform bionic feedback technology with dual clinical applications, which points to a broader medtech commercialisation play rather than a niche device company.

How they like to work

Saphenus has acted as coordinator on both of their H2020 projects, which is consistent with the SME Instrument funding scheme — a programme specifically designed for single-company innovation grants rather than multi-partner consortia. As a result, they have no recorded consortium partners in H2020, meaning they are an independent innovator rather than a network hub. Working with them would likely mean engaging them directly as a technology provider or clinical partner, not as part of an established research network.

Saphenus has no recorded consortium partners across their two H2020 projects, which is expected given their exclusive use of the SME Instrument — a solo-company funding track. Their formal European research network is therefore minimal, though their commercial and clinical networks are not visible in this data.

What sets them apart

Saphenus is one of the few Austrian medical technology SMEs to have completed the full SME Instrument arc — from Phase 1 feasibility to Phase 2 full development — in the prosthetics and bionic feedback space. Their dual focus on amputees and diabetics positions them at the intersection of prosthetics and chronic disease management, a combination that is commercially attractive given the scale of the diabetic population at risk of amputation. For consortium builders, they bring proprietary device technology and clinical application focus rather than academic research capacity.

Highlights from their portfolio

• BFS
  At EUR 1,806,000 this is the company's flagship project and one of the larger SME Instrument Phase 2 awards, developing a bionic feedback system for both amputees and diabetics — a dual-indication approach that broadens the commercial addressable market.
• IPS
  The Phase 1 feasibility study that validated the intelligent prosthesis concept and opened the pathway to the much larger BFS Phase 2 grant, demonstrating a disciplined EU funding progression.